Five analysts have provided ratings on Axonics (NASDAQ:AXNX) with diverse perspectives ranging from bullish to bearish. Over the last three months, there have been 2 bullish and 3 somewhat bullish ratings, with no changes in the past 30 days. The average 12-month price target is $70.0, with a high of $75.00 and a low of $63.00, marking a decrease from the previous average of $75.25. Analysts from Truist Securities, Piper Sandler, Morgan Stanley, Needham, and Leerink Partners have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Axonics, a medical technology company, has shown a revenue growth of 32.27% as of September 30, 2023, and has a market capitalization below the industry average. It also boasts a net margin of 4.22%, ROE of 0.65%, ROA of 0.6%, and a debt-to-equity ratio of 0.0.